XIENCE V - a DES with superior* outcomes that can take your performance to new heights. Abbott’s XIENCE V is truly a next-generation DES, combining the proven deliverability of the MULTI-LINK VISION stent platform with a Multi-layer Coating Technology and everolimus to deliver superior* outcomes for patients with coronary artery disease (CAD).

 

---

*XIENCE V has demonstrated statistical superiority against Taxus Express in the primary endpoints of SPIRIT IV, SPIRIT III and SPIRIT II in target lesion failure, in-segment late loss and in-stent late loss respectively. Source: SPIRIT IV 1-year results, Gregg Stone, TCT 2009 and data on file at Abbott Vascular.